menu
    • menu
    [{"orgOrder":0,"company":"Synthorx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"THOR-707","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Synthorx","amount2":2.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":2.5,"dosageForm":"","sponsorNew":"Synthorx \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Synthorx \/ Sanofi"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"THOR-707","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Sanofi"},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Synthorx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"THOR-707","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Synthorx","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Therapeutics \/ Synthorx"}]

    Find Clinical Drug Pipeline Developments & Deals for THOR-707

    Menu

    THOR-707

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImCheck Therapeutics

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ImCheck Therapeutics

                            France arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THOR-707,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Synthorx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Interim Late-Breaking Clinical Data Validate Not-Alpha Profile of THOR-707 (SAR444245), Sanofi’s Novel Inves...

                            Details : THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors.

                            Brand Name : THOR-707

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 09, 2021

                            Lead Product(s) : THOR-707,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Synthorx

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merck & Co

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THOR-707,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sanofi Teams Up with Merck to Pair Keytruda with a Next-Gen IL-2 Candidate from the Synthorx Buyout

                            Details : The Phase 2 clinical trial aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of THOR-707, a highly differentiated non-alpha IL-2 candidate combined with or in sequenced administration with MSD’s KEYTRUDA® (pembrolizumab) in patie...

                            Brand Name : THOR-707

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : THOR-707,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synthorx

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Synthorx

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THOR-707

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : $2,500.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi announced today the successful completion of its acquisition of Synthorx, Inc

                            Details : Under the terms and conditions of the deal, Synthorx’ lead candidate THOR-707 is being tested against multiple tumour types, and will also be tested in combination with Sanofi’s own cancer drugs.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 23, 2020

                            Lead Product(s) : THOR-707

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : $2,500.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth